Open NebulaBack to home
Back to Resources
November 5, 2026Stocks·Bullish·m&a

Evommune licenses Hinova autoimmune drug in deal worth up to $1.1 billion

Evommune has licensed an autoimmune drug from Hinova in a deal worth up to $1.1 billion.

Detected & updated continuously · Source: Nebula

Story subjects

Evommune, Inc.

Track sentiment and mindshare across stocks and crypto in Nebula.

Open Nebula